ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2025
Impact of kidney function on biomarkers of neurodegeneration, white matter hyperintensities, and cognition in older adults.
Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Chronic kidney disease and cognitive decline: choroid plexus remodeling, glymphatic dysfunction, and alzheimer biomarker interpretation.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026Review
- Chronic Kidney disease and cognitive frailty in aging: molecular crosstalk and clinical implications.Frontiers in aging neuroscience · 2026Review
- Impact of kidney function on biomarkers of neurodegeneration, white matter hyperintensities, and cognition in older adults.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Plasma p-tau217 and cognitive impairment: Evaluating biomarker equity across racial/ethnic groups in HABS-HD.Alzheimer's & dementia (Amsterdam, Netherlands)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundWe evaluated the association between kidney function, neurodegenerative biomarkers (i.e., neurofilament light chain [NfL], total tau [t-tau], and glial fibrillary acidic protein [GFAP]), white matter hyperintensities, and global cognition.
methodsThe study consisted of 1207 participants living on the south side of Chicago, Illinois, enrolled in the Chicago Health and Aging Project, a population-based cohort since 1993. Kidney function was assessed using the estimated glomerular filtration rate (eGFRcr), calculated according to the 2021 Chronic Kidney Disease Epidemiology (CKD-EPI) based on age, sex, and serum creatinine levels.
resultsIn a multivariable-adjusted model, lower levels of eGFRcr were associated with higher levels of biomarkers of neurodegeneration. Specifically, for a 1-SD decrease of eGFRcr, there was a 22% increase in NfL levels in serum. eGFRcr levels were not associated with white matter hyperintensities or global cognition. DISCUSSION: Kidney function may be considered when interpreting NfL, GFAP, and t-tau levels for risk stratification in research and clinical applications. HIGHLIGHTS: Kidney function is associated with higher neurfilament light chain (NfL), total tau (t-tau), and glial fibrillary acidic protein (GFAP) serum concentrations, while there was no association with white matter hyperintensities or global cognition. Individuals with severely impaired kidney function had 146.7% higher serum concentrations of NfL when compared to people with normal kidney function. This study suggests assessing kidney function in older adults when interpreting NfL, GFAP, and t-tau levels in the serum for risk stratification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.